Update of the recommendations of the Italian Society of Medical Oncology on vaccination for seasonal influenza and pneumococcal infection in patients with cancer: Focus on prevention of pneumonia

Pedrazzoli, Paolo; Piralla, Antonio; Valentino, Francesco; Cinieri, Saverio; Baldanti, Fausto

doi:10.1111/ecc.12817

Cited by 8 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased risk of invasive pneumococcal infection was already reported in cancer patients [ 22 , 23 ]. Our results of higher incidence of pneumococcal infection and of poorer prognosis among cancer patients are of utmost importance, as therapeutic advances in cancer management itself continue to progress and the number of cancer survivors is more and more increasing.…”

Section: Discussionmentioning

confidence: 99%

The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia

Blanc

Chaize²,

Fievez

et al. 2021

BMC Infect Dis

View full text Add to dashboard Cite

Background The prognosis of patients hospitalized with community-acquired pneumonia (CAP) with regards to intensive care unit (ICU) admission, short- and long-term mortality is correlated with patient’s comorbidities. For patients hospitalized for CAP, including P-CAP, we assessed the prognostic impact of comorbidities known as at-risk (AR) or high-risk (HR) of pneumococcal CAP (P-CAP), and of the number of combined comorbidities. Methods Data on hospitalizations for CAP among the French 50+ population were extracted from the 2014 French Information Systems Medicalization Program (PMSI), an exhaustive national hospital discharge database maintained by the French Technical Agency of Information on Hospitalization (ATIH). Their admission diagnosis, comorbidities (nature, risk type and number), other characteristics, and their subsequent hospital stays within the year following their hospitalization for CAP were analyzed. Logistic regression models were used to assess the associations between ICU transfer, short- and 1-year in-hospital mortality and all covariates. Results From 182,858 patients, 149,555 patients aged ≥ 50 years (nonagenarians 17.8%) were hospitalized for CAP in 2014, including 8270 with P-CAP. Overall, 33.8% and 90.5% had ≥ 1 HR and ≥ 1 AR comorbidity, respectively. Cardiac diseases were the most frequent AR comorbidity (all CAP: 77.4%). Transfer in ICU occurred for 5.4% of CAP patients and 19.4% for P-CAP. Short-term and 1-year in-hospital mortality rates were 10.9% and 23% of CAP patients, respectively, significantly lower for P-CAP patients: 9.2% and 19.8% (HR 0.88 [95% CI 0.84–0.93], p < .0001). Both terms of mortality increased mostly with age, and with the number of comorbidities and combination of AR and HR comorbidities, in addition of specific comorbidities. Conclusions Not only specific comorbidities, but also the number of combined comorbidities and the combination of AR and HR comorbidities may impact the outcome of hospitalized CAP and P-CAP patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia

Blanc

Chaize²,

Fievez

et al. 2021

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…Specific evidence-based recommendations on influenza vaccination in patients with cancer were issued in 2014 by the Italian Society of Medical Oncology (AIOM) [8]. These recommendations, which are regularly updated [9,10,12], state that influenza vaccination is an effective, safe, non-invasive, and relatively inexpensive measure to prevent influenzaassociated complications in patients with cancer [8]. According to the AIOM guidelines, influenza vaccination should be given to all patients with cancer, regardless of whether they are receiving anticancer therapy or not, including those receiving biologics for solid tumors.…”

Section: Current Recommendationsmentioning

confidence: 99%

“…Owing to disease and/or treatment-associated immunosuppression, patients with cancer are vulnerable to infectious diseases and are at high risk of developing infectionrelated complications, including those associated with influenza [7]. Vaccination against common preventable diseases, including seasonal influenza, is therefore highly recommended in these patients [5,[8][9][10][11][12]. However, evidence suggests that the rates of influenza vaccination in this high-risk group are far below the recommended goal of ≥75% coverage [13,14].…”

Section: Introductionmentioning

confidence: 99%

Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group

Bonanni,

Maio,

Beretta

et al. 2024

Vaccines

View full text Add to dashboard Cite

Patients with cancer can be immunocompromised because of their disease and/or due to anticancer therapy. In this population, severe influenza virus infections are associated with an elevated risk of morbidity and mortality. Influenza vaccination is therefore highly recommended in cancer patients, including those receiving anticancer therapy. However, vaccination coverage remains far below the recommended target for vulnerable subjects. Six specialists in oncology, hematology, immunology, and public health/vaccinology convened with the objective of developing strategies, based on evidence and clinical experience, for improving influenza vaccination coverage in cancer patients. This viewpoint provides an overview of current influenza vaccination recommendations in cancer patients, discusses barriers to vaccination coverage, and presents strategies for overcoming said barriers. New immunization issues raised by the COVID-19 pandemic are also addressed. Future directions include improving public education on influenza vaccination, providing the media with accurate information, improving knowledge among healthcare professionals, improving access to vaccines for cancer patients, co-administration of the influenza and COVID-19 vaccines, increased collaboration between oncologists and other health professionals, increased accessibility of digital vaccination registries to specialists, shared information platforms, and promoting immunization campaigns by healthcare systems with the support of scientific societies.

show abstract

“…The Italian Association of Medical Oncology (AIOM) has been involved in vaccination awareness since 2014. The first recommendations on seasonal flu vaccination were published in 2014 [ 7 ] and they were subsequently updated and implemented with those on pneumococcal vaccination in 2018 [ 8 ]. More recently, AIOM has published the recommendations about the vaccination for herpes zoster [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

Pedrazzoli¹,

Lasagna²,

Cassaniti³

et al. 2023

ESMO Open

View full text Add to dashboard Cite

Update of the recommendations of the Italian Society of Medical Oncology on vaccination for seasonal influenza and pneumococcal infection in patients with cancer: Focus on prevention of pneumonia

Cited by 8 publications

References 5 publications

The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia

The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia

Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

Contact Info

Product

Resources

About